Context Therapeutics Inc
contexttherapeutics.comContext Therapeutics Inc (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibody therapies for cancer. The company generates no product revenue. All cash consumption funds research and development expenditures and general and administrative costs. As of December 31, 2025, Context held $66.0 million in cash and cash equivalents. Its lead programs include CT-202, a T-cell engager targeting Nectin-4, for which the company submitted an application to the Human Research Ethics Committee in March 2026 to support a first-in-human trial, with first patient dosing targeted for the third quarter of 2026. A CLDN6 bispecific antibody program originated from a collaboration and license agreement with Integral Molecular, Inc., signed in April 2021, under which Context holds exclusive worldwide rights to develop and commercialize the asset. The company funds operations through equity issuances, including an at-the-market facility with Leerink Partners LLC allowing sales of up to $75.0 million in common stock as of October 2025.
Products & Services
CT-202: a T-cell engager (TCE) bispecific antibody targeting Nectin-4, designed to target tumors with varying levels of Nectin-4 expression; first-in-human Phase 1 trial targeted for initiation in Q3 2026. CLDN6 bispecific antibody: a T-cell engaging antibody intended to activate T cells against cancer cells displaying Claudin-6 (CLDN6), developed under a collaboration and license agreement with Integral Molecular, Inc. (signed April 2021).
Revenue Model
No product revenue as of the fiscal year ended December 31, 2025. Operations are funded through equity financings, including at-the-market common stock offerings and private placements. The company incurs net operating losses and expects to continue doing so through clinical development and potential commercialization.
Customers & Markets
No commercial customers as of December 31, 2025. End market is oncology, targeting patients with cancers expressing Nectin-4 or CLDN6 antigens. Programs are in pre-commercial clinical and preclinical stages.
Geographic Exposure
Incorporated and headquartered in the United States. Clinical trial regulatory interactions noted with the Australian Therapeutic Goods Administration (TGA) in connection with the CT-202 program. Exclusive worldwide development and commercialization rights held for CLDN6 bispecific antibody program.
Financial Snapshot
Loading...
